论文部分内容阅读
骨髓活检(BMB)对恶性淋巴瘤(ML)的诊断、预后判断、评价治疗反应及检测残余病灶都至关重要。作者对过去10年间443例非何杰金淋巴瘤(NHL)与155例何杰金病(HD)病人的BMB结果进行回顾性研究,着重探讨其临床病理的关系。上述病人的BMB时均未接受治疗,除常规形态学观察外,还对26例NHL及10例HD病人切片进行了免疫组化观察。免疫组比采用APAAP法,选用F8、11、13,A6,Kim-6及BerH_2单克隆抗体,分别识别B细胞、T细胞、骨髓巨噬细胞及组织细胞、HD
Bone marrow biopsy (BMB) is crucial for the diagnosis, prognosis assessment, evaluation of treatment response, and detection of residual lesions in malignant lymphoma (ML). The authors retrospectively studied the BMB results of 443 patients with non-Hodgkin’s lymphoma (NHL) and 155 patients with Hodgkin’s disease (HD) in the past 10 years, focusing on the relationship between their clinical pathology. The above-mentioned patients were not treated with BMB at all times. In addition to routine morphological observations, 26 cases of NHL and 10 cases of HD patients were also observed by immunohistochemistry. The APAAP method was used in the immunization group. F8, 11, 13, A6, Kim-6 and BerH2 monoclonal antibodies were selected to identify B cells, T cells, bone marrow macrophages, and histiocytes, respectively.